Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Royal Bank of Canada — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $109.67 (market cap $12.58B), while Royal Bank of Canada trades at $193.65 (market cap $265.72B). The key difference: Royal Bank of Canada is far larger — about 21.1× Halozyme Therapeutics Inc. Common Stock's market cap, and Royal Bank of Canada pays a 2.65% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Royal Bank of Canada for 47 Days on average.
| HALO | RY | |
|---|---|---|
Market Cap | $12.58B | $265.72B |
Volume | 2,179,278 | 756,291 |
Sector | Health | Financials |
52-Week High | $115.22 | $217.87 |
52-Week Low | $61.63 | $143.64 |
Typical Hold Time | 0 Days | 47 Days |
Enterprise Value | $14.49B | $732.82B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Royal Bank of Canada (RY) trades at $190.56, down 2.95% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $3.07 beating estimates of $2.89 (Zacks Investment Research, August 27, 2026). Revenue growth accelerated to $66.53B in 2025, with net income margin improving to 32.01%. The company maintains a solid dividend payout of $1.76 per share, with the next payment scheduled for November 24, 2026.
RY presents a mixed investment case with strong profitability and dividend stability offset by stretched valuations and bearish technical indicators. The 17.2 P/E ratio suggests fair valuation, while analyst consensus leans neutral with 43% buy ratings. Key risks include macroeconomic sensitivity and competitive pressures in financial services. The stock's current technical weakness near support at $189 may present entry opportunities for long-term investors seeking quality banking exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
